Lipegfilgrastim
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Lipegfilgrastim
- Lipegfilgrastim: From Chemotherapy-Induced Neutropenia to Primary Release Disorder of Platelets
Lipegfilgrastim: From Chemotherapy-Induced Neutropenia to Primary Release Disorder of Platelets
One-Sentence Summary
Lipegfilgrastim is a pegylated recombinant human G-CSF analog known clinically for treating chemotherapy-induced neutropenia. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only hypothesis with no empirical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chemotherapy-induced neutropenia (based on known drug class information; not confirmed in the source evidence pack) |
| Predicted New Indication | Primary Release Disorder of Platelets |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information, Lipegfilgrastim is a pegylated recombinant human G-CSF analog that stimulates proliferation and differentiation of granulocyte (neutrophil) precursor cells in bone marrow, and its efficacy in chemotherapy-induced neutropenia is well established.
However, the predicted new indication — primary release disorder of platelets — involves a pathology of defective platelet granule content release, a mechanism with no known overlap with neutrophil-stimulating G-CSF activity. The evidence pack's own mechanistic assessment explicitly states there is no verifiable biological pathway connecting the two, and this ranking (score 0.9993, graph rank 1044) reflects TxGNN knowledge-graph association scoring alone, not a validated pharmacological hypothesis.
The remaining four predicted indications in this evidence pack (severe nonproliferative diabetic retinopathy, pseudo-von Willebrand disease, Glanzmann thrombasthenia, diabetic retinopathy) show similarly weak or speculative mechanistic links — ranging from an unproven endothelial-progenitor-cell mobilization hypothesis to structurally/genetically defined platelet disorders with no cytokine-modulated pathway. None currently rise above L5 (model prediction only).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Lipegfilgrastim is not currently marketed in Norway (0 authorizations on record). No product license data is available.
Safety Considerations
Please refer to the package insert for safety information.
Note: A Blocking-severity data gap (DG001) exists for TFDA warning/contraindication data, which prevents this candidate from entering the S1 safety pre-assessment stage.
Conclusion and Next Steps
Decision: Hold
Rationale: All five predicted indications remain at evidence stage S0 (model prediction only) with no supporting clinical trials or literature, and a Blocking-severity safety data gap prevents progression to formal safety pre-assessment. The mechanistic rationale for the top prediction is explicitly assessed as lacking biological plausibility.
To proceed, the following is needed:
- TFDA/regulatory warning and contraindication data (Blocking gap, DG001) — required before any S1 safety review
- Confirmed original mechanism of action (MOA) data via DrugBank API (High-priority gap, DG002)
- Independent literature or preclinical evidence establishing a biological pathway between G-CSF activity and platelet release/function disorders
- Registration of dedicated clinical trials, or identification of existing off-label case data, for any of the five candidate indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.